{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:00:31Z","timestamp":1787760031740,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["24K11440"],"award-info":[{"award-number":["24K11440"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40991-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:36:55Z","timestamp":1772210215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of anemia with long-term renal prognosis in autosomal dominant polycystic kidney disease using time-series analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Hiroshi","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Akihisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Otsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Hanafusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"40991_CR1","doi-asserted-by":"crossref","unstructured":"Chapman, A. B. et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international. 88, 17\u201327 (2015).","DOI":"10.1038\/ki.2015.59"},{"key":"40991_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki, T., Tsuchiya, K. & Nitta, K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin. Exp. Nephrol. 17, 317\u2013326 (2013).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ekir.2021.12.012","volume":"7","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Germline Mutations for Kidney Volume in ADPKD. Kidney Int. Rep. 7, 537\u2013546 (2022).","journal-title":"Kidney Int. Rep."},{"key":"40991_CR4","first-page":"e000203","volume":"2","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Mutation Type and Intracranial aneurysm formation in autosomal dominant polycystic kidney disease. Stroke: Vascular Interventional Neurol. 2, e000203 (2022).","journal-title":"Stroke: Vascular Interventional Neurol."},{"key":"40991_CR5","doi-asserted-by":"publisher","first-page":"18056","DOI":"10.1038\/s41598-022-22884-9","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Sci. Rep. 12, 18056\u201318056 (2022).","journal-title":"Sci. Rep."},{"key":"40991_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12072-021-10176-9","volume":"15","author":"H Kataoka","year":"2021","unstructured":"Kataoka, H. et al. Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease. Hep. Intl. 15, 791\u2013803 (2021).","journal-title":"Hep. Intl."},{"key":"40991_CR7","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","volume":"25","author":"S Nishio","year":"2021","unstructured":"Nishio, S. et al. A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020. Clin. Exp. Nephrol. 25, 1292\u20131302 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall, E., Alam, A. & Perrone, R. D. Autosomal dominant polycystic kidney disease. Lancet 393, 919\u2013935 (2019).","journal-title":"Lancet"},{"key":"40991_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2215\/CJN.03250410","volume":"6","author":"VE Torres","year":"2011","unstructured":"Torres, V. E. et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrology: CJASN. 6, 640\u2013647 (2011).","journal-title":"Clin. J. Am. Soc. Nephrology: CJASN"},{"key":"40991_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10157-012-0611-9","volume":"16","author":"E Higashihara","year":"2012","unstructured":"Higashihara, E. et al. Renal disease progression in autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 16, 622\u2013628 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-015-0114-5","volume":"16","author":"C Woon","year":"2015","unstructured":"Woon, C., Bielinski-Bradbury, A., O\u2019Reilly, K. & Robinson, P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 16, 140 (2015).","journal-title":"BMC Nephrol."},{"key":"40991_CR12","doi-asserted-by":"crossref","unstructured":"Kataoka, H. et al. Prediction of renal prognosis in patients with autosomal dominant polycystic kidney disease using PKD1\/PKD2 ,mutations. J. Clin. Med. 9 (2020).","DOI":"10.3390\/jcm9010146"},{"key":"40991_CR13","doi-asserted-by":"crossref","unstructured":"Nitta, K. et al. Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. (2024).","DOI":"10.1681\/ASN.2024kxwavxwp"},{"key":"40991_CR14","doi-asserted-by":"publisher","first-page":"e0215920","DOI":"10.1371\/journal.pone.0215920","volume":"14","author":"SW Yi","year":"2019","unstructured":"Yi, S. W., Moon, S. J. & Yi, J. J. Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: A prospective cohort study. PloS one. 14, e0215920 (2019).","journal-title":"PloS one"},{"key":"40991_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2369-14-2","volume":"14","author":"J Portoles","year":"2013","unstructured":"Portoles, J. et al. The development of anemia is associated to poor prognosis in NKF\/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 14, 2 (2013).","journal-title":"BMC Nephrol."},{"key":"40991_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","volume":"30","author":"J Hoshino","year":"2020","unstructured":"Hoshino, J. et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3\u20135 nondialysis CKD. J. Ren. Nutr. 30, 404\u2013414 (2020).","journal-title":"J. Ren. Nutr."},{"key":"40991_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ndt\/gfm717","volume":"23","author":"EA de Almeida","year":"2008","unstructured":"de Almeida, E. A. et al. Haemoglobin and erythropoietin levels in polycystic kidney disease. Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association. 23, 412\u2013413 (2008).","journal-title":"Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association"},{"key":"40991_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000183332","volume":"39","author":"M Chandra","year":"1985","unstructured":"Chandra, M., Miller, M. E., Garcia, J. F., Mossey, R. T. & McVicar, M. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 39, 26\u201329 (1985).","journal-title":"Nephron"},{"key":"40991_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1172\/JCI114280","volume":"84","author":"KU Eckardt","year":"1989","unstructured":"Eckardt, K. U. et al. Erythropoietin in polycystic kidneys. J. Clin. Investig. 84, 1160\u20131166 (1989).","journal-title":"J. Clin. Investig."},{"key":"40991_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10157-020-01856-1","volume":"24","author":"Y Ushio","year":"2020","unstructured":"Ushio, Y. et al. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Clin. Exp. Nephrol. 24, 500\u2013508 (2020).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000531329","volume":"9","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Development and validation of a nomogram for renal survival prediction in patients with autosomal dominant polycystic kidney disease. Kidney Dis. (Basel). 9, 398\u2013407 (2023).","journal-title":"Kidney Dis. (Basel)"},{"key":"40991_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei, Y. et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol. JASN. 20, 205\u2013212 (2009).","journal-title":"J. Am. Soc. Nephrology: JASN"},{"key":"40991_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber, A. B. et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 19, 300\u2013315 (2016).","journal-title":"Value Health"},{"key":"40991_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"CL Gall","year":"2016","unstructured":"Gall, C. L. The PROPKD Score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrology: JASN. 27, 942\u2013951 (2016).","journal-title":"J. Am. Soc. Nephrology: JASN"},{"key":"40991_CR25","doi-asserted-by":"crossref","unstructured":"Sato, M. et al. High serum phosphate level as a risk factor to determine renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Med. (Basel) 7 (2020).","DOI":"10.3390\/medicines7030013"},{"key":"40991_CR26","doi-asserted-by":"crossref","unstructured":"Kataoka, H. et al. Impacts of sex differences in pulse pressure among patients with chronic kidney disease. J Pers. Med 9 (2019).","DOI":"10.3390\/jpm9040052"},{"key":"40991_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s00380-019-01375-4","volume":"34","author":"K Kawachi","year":"2019","unstructured":"Kawachi, K., Kataoka, H., Manabe, S., Mochizuki, T. & Nitta, K. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis. Heart Vessels. 34, 1440\u20131455 (2019).","journal-title":"Heart Vessels"},{"key":"40991_CR28","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1111\/bph.12856","volume":"172","author":"MJ Curtis","year":"2015","unstructured":"Curtis, M. J. et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol. 172, 3461\u20133471 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"40991_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff, E. & McCulloch, C. E. Relaxing the rule of ten events per variable in logistic and Cox regression. Am. J. Epidemiol. 165, 710\u2013718 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"40991_CR30","doi-asserted-by":"crossref","unstructured":"Kataoka, H. et al. Sex differences in time-series changes in pseudo-R2 values regarding hyperuricemia in relation to the kidney prognosis. J. Personalized Med. 10 (2020).","DOI":"10.3390\/jpm10040248"},{"key":"40991_CR31","doi-asserted-by":"publisher","first-page":"e0232885","DOI":"10.1371\/journal.pone.0232885","volume":"15","author":"H Kataoka","year":"2020","unstructured":"Kataoka, H. et al. Time series changes in pseudo-R2 values regarding maximum glomerular diameter and the Oxford MEST-C score in patients with IgA nephropathy: A long-term follow-up study. PloS one. 15, e0232885 (2020).","journal-title":"PloS one"},{"key":"40991_CR32","doi-asserted-by":"publisher","first-page":"e0241626","DOI":"10.1371\/journal.pone.0241626","volume":"15","author":"H Kataoka","year":"2020","unstructured":"Kataoka, H. et al. Visceral to subcutaneous fat ratio as an indicator of a >\/=30% eGFR decline in chronic kidney disease. PloS one. 15, e0241626 (2020).","journal-title":"PloS one"},{"key":"40991_CR33","doi-asserted-by":"crossref","unstructured":"Kataoka, H. et al. Maximum glomerular diameter and oxford MEST-C score in IgA nephropathy: The significance of time-series changes in pseudo-R(2) values in relation to renal outcomes. J. Clin. Med. 8 (2019).","DOI":"10.3390\/jcm8122105"},{"key":"40991_CR34","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer, M. E. & Fan, T. Prevalence of anemia in chronic kidney disease in the United States. PloS one. 9, e84943 (2014).","journal-title":"PloS one"},{"key":"40991_CR35","doi-asserted-by":"publisher","first-page":"e0236132","DOI":"10.1371\/journal.pone.0236132","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue, T. et al. Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PloS one. 15, e0236132 (2020).","journal-title":"PloS one"},{"key":"40991_CR36","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. Hypoxia, HIF, and associated signaling networks in chronic kidney disease. Int J. Mol. Sci 18 (2017).","DOI":"10.3390\/ijms18050950"},{"key":"40991_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1056\/NEJMra1011165","volume":"365","author":"GL Semenza","year":"2011","unstructured":"Semenza, G. L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365, 537\u2013547 (2011).","journal-title":"N. Engl. J. Med."},{"key":"40991_CR38","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","volume":"94","author":"A Kraus","year":"2018","unstructured":"Kraus, A. et al. HIF-1alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 94, 887\u2013899 (2018).","journal-title":"Kidney Int."},{"key":"40991_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.kint.2018.07.012","volume":"94","author":"A Hofherr","year":"2018","unstructured":"Hofherr, A., Busch, T. & Kottgen, M. HIF-1alpha drives cyst growth in advanced stages of autosomal dominant polycystic kidney disease. Kidney Int. 94, 849\u2013851 (2018).","journal-title":"Kidney Int."},{"key":"40991_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1681\/ASN.2013030209","volume":"25","author":"B Buchholz","year":"2014","unstructured":"Buchholz, B. et al. Hypoxia-inducible factor-1alpha causes renal cyst expansion through calcium-activated chloride secretion. J. Am. Soc. Nephrology: JASN. 25, 465\u2013474 (2014).","journal-title":"J. Am. Soc. Nephrology: JASN"},{"key":"40991_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1053\/j.ajkd.2009.12.042","volume":"56","author":"DV Vlahakos","year":"2010","unstructured":"Vlahakos, D. V., Marathias, K. P. & Madias, N. E. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am. J. kidney diseases: official J. Natl. Kidney Foundation. 56, 558\u2013565 (2010).","journal-title":"Am. J. kidney diseases: official J. Natl. Kidney Foundation"},{"key":"40991_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000501021","volume":"44","author":"H Kataoka","year":"2019","unstructured":"Kataoka, H. et al. A body mass index-based cross-classification approach for the assessment of prognostic factors in chronic kidney disease progression. Kidney Blood Press. Res. 44, 362\u2013383 (2019).","journal-title":"Kidney Blood Press. Res."},{"key":"40991_CR43","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1038\/s41598-022-07737-9","volume":"12","author":"H Kataoka","year":"2022","unstructured":"Kataoka, H. et al. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study. Sci. Rep. 12, 3784 (2022).","journal-title":"Sci. Rep."},{"key":"40991_CR44","doi-asserted-by":"crossref","unstructured":"Kataoka, H., Nitta, K. & Hoshino, J. Visceral fat and attribute-based medicine in chronic kidney disease. Front. Endocrinol. 14 (2023).","DOI":"10.3389\/fendo.2023.1097596"},{"key":"40991_CR45","unstructured":"Kataoka, H. et al. Attribute-based medicine for IgAnephropathy: risk factor constellations influence kidney prognosis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association (2025)."},{"key":"40991_CR46","doi-asserted-by":"publisher","first-page":"23221","DOI":"10.1038\/s41598-025-05762-y","volume":"15","author":"H Kataoka","year":"2025","unstructured":"Kataoka, H. et al. Attribute based cross classification analyses from the BRIGHTEN study reveal that therapeutic responsiveness to erythropoiesis stimulating agents predicts cardiorenal prognosis in renal anemia. Sci. Rep. 15, 23221 (2025).","journal-title":"Sci. Rep."},{"key":"40991_CR47","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1093\/ndt\/gfaf095","volume":"40","author":"H Kataoka","year":"2025","unstructured":"Kataoka, H. et al. Middle cerebral artery aneurysms in older women with autosomal dominant polycystic kidney disease. Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association. 40, 2118\u20132130 (2025).","journal-title":"Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association"},{"key":"40991_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","volume":"28","author":"WG Murphy","year":"2014","unstructured":"Murphy, W. G. The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev. 28, 41\u201347 (2014).","journal-title":"Blood Rev."},{"key":"40991_CR49","doi-asserted-by":"crossref","unstructured":"Tsubakihara, Y. et al. Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Therapeutic Apheresis and Dialysis. 14, 240\u2013275 (2010). (2008).","DOI":"10.1111\/j.1744-9987.2010.00836.x"},{"key":"40991_CR50","doi-asserted-by":"crossref","unstructured":"Yamamoto, H. et al. Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. Renal Replacement Therapy. 3, 36 (2017). (2015).","DOI":"10.1186\/s41100-017-0114-y"},{"key":"40991_CR51","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli, F. et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association. 28, 1346\u20131359 (2013).","journal-title":"Nephrol. dialysis transplantation: official publication Eur. Dialysis Transpl. Association - Eur. Ren. Association"},{"key":"40991_CR52","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","volume":"82","author":"TB Drueke","year":"2012","unstructured":"Drueke, T. B. & Parfrey, P. S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 82, 952\u2013960 (2012).","journal-title":"Kidney Int."},{"key":"40991_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10157-014-0948-3","volume":"18","author":"K Kimura","year":"2014","unstructured":"Kimura, K. Preface: evidence-based clinical practice guidelines for CKD: an abridged English version. Clin. Exp. Nephrol. 18, 339\u2013340 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","volume":"23","author":"Japanese Society of, N","year":"2019","unstructured":"Japanese Society of, N. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin. Exp. Nephrol. 23, 1\u201315 (2019).","journal-title":"Clin. Exp. Nephrol."},{"key":"40991_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10157-024-02497-4","volume":"28","author":"Japanese Society of, N","year":"2024","unstructured":"Japanese Society of, N. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin. Exp. Nephrol. 28, 473\u2013495 (2024).","journal-title":"Clin. Exp. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40991-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:02:15Z","timestamp":1775250135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40991-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40991"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40991-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshio Mochizuki and Hiroshi Kataoka belonged to an endowed department sponsored by Otsuka Pharmaceutical Co., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., and JMS Co. The remaining authors declare no conflicts of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11277"}}